secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001104659-26-011595
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel enters retention bonus agreements with key employees, CEO gets $650K after sNDA submission
--------------------------------------------------------------------------------

- CEO receives $650K bonus ($325K initial, $325K final); other key employees get $225K ($150K initial, $75K final).
- Final payment due April 15, 2026, contingent on continued employment and no default under Oaktree credit agreement.
- Final payment accelerates if company raises $25M+ capital or a change of control occurs before April 15, 2026.
- Employees must repay bonuses if terminated for cause or resign without good reason before Dec 31, 2026 (or Sep 30, 2026 if only initial paid).
- Agreements follow submission of sNDA for IGALMI for acute agitation in bipolar disorder or schizophrenia in outpatient setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926011595/0001104659-26-011595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926011595/tm265449d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-011595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer